Pembrolizumab plus axitinib shows sustained benefit in advanced kidney cancer
The final long-term follow-up data from the phase 3 KEYNOTE-426 [...]
Adjuvant pembrolizumab prolongs overall survival for kidney cancer patients
Surgery (partial or radical nephrectomy) is the standard of care [...]
Lenvatinib plus pembrolizumab for advanced kidney cancer
The final survival information from the phase 3 CLEAR study [...]
Corticosteroids during treatment with nivolumab may not affect survival in kidney cancer
A recent study published in the journal JAMA Oncology has [...]
Stopping smoking after kidney cancer diagnosis may reduce the risk of cancer progression and death
A recent study looked at whether stopping smoking after a [...]
Psychological distress in patients treated for kidney cancer
This review of the literature looked at how common psychological [...]
BMI and outcomes in patients with metastatic kidney cancer treated with first-line TKIs
This study looked at whether high or low body mass [...]
Survival after second-line therapy in patients with metastatic kidney cancer treated with first-line immunotherapy combinations
This study looked at real world information from patients with [...]
Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times
When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]
Nivolumab compared to cabozantinib as a second- or third-line treatment
This study looked at real world data from people with [...]
